Lyell Immunopharma, Inc. — Director's Dealing 2025

Oct 29, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-10-27

Reporting Person: Lee Gary K. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-10-27	Option (right to buy)	$17.23	A	68000	Acquired	2035-10-26	Common Stock (68000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	15504	Direct

Footnotes

F1: 12.5% of the option shares will vest on April 27, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.